Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

Curaleaf has launched a hostile takeover bid for Aurora Cannabis (ACB) at $4 per share, which ACB's board has rejected. The offer values the company at a price that may undervalue Aurora's recent operational transformation and international footprint, according to analysis from The Motley Fool.

Aurora has pivoted from its troubled past into a profitable medical cannabis operation with strong European presence and an improved balance sheet. The company's medical cannabis turnaround and international expansion represent genuine operational progress that could justify a higher valuation than Curaleaf's current bid.

However, the deal faces significant uncertainty. There is no guarantee Curaleaf will raise its $4-per-share offer or that the transaction will close at all. Aurora's board rejection signals management believes the bid undervalues the company's prospects.

The hostile nature of the bid sets up a potential standoff between the two cannabis operators, with Aurora's management likely to defend its independent strategy focused on medical cannabis and European markets.